User profiles for MARK TRUTY
 | Mark J. TrutyMayo Clinic College of Medicine Verified email at mayo.edu Cited by 7208 |
[HTML][HTML] Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer
MJ Truty, ML Kendrick, DM Nagorney, RL Smoot… - Annals of …, 2021 - journals.lww.com
Objective: To identify predictive factors associated with operative morbidity, mortality, and
survival outcomes in patients with borderline resectable (BR) or locally advanced (LA) …
survival outcomes in patients with borderline resectable (BR) or locally advanced (LA) …
Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in …
Importance Although consensus statements support the preoperative treatment of borderline
resectable pancreatic cancer, no prospective, quality-controlled, multicenter studies of this …
resectable pancreatic cancer, no prospective, quality-controlled, multicenter studies of this …
Indications and perioperative outcomes for pancreatectomy with arterial resection
Background Pancreatectomy with arterial resection (AR) is performed infrequently. As indications
evolve, we evaluated indications, outcomes, and predictors of mortality, morbidity, and …
evolve, we evaluated indications, outcomes, and predictors of mortality, morbidity, and …
Pancreaticoduodenectomy with major vascular resection: a comparison of laparoscopic versus open approaches
…, FG Que, KM Reid-Lombardo, MJ Truty… - Journal of …, 2015 - Elsevier
Background Major vascular resection when necessary for margin control during
pancreaticoduodenectomy is relatively universal with perioperative and oncological outcomes that …
pancreaticoduodenectomy is relatively universal with perioperative and oncological outcomes that …
[PDF][PDF] Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the …
…, PD Conway, TR Halfdanarson, MJ Truty… - Journal of Clinical …, 2018 - llusurgonc.org
Purpose Data that guide selection of optimal local ablative therapy for the management
localized hepatocellular carcinoma (HCC) are lacking. Because there are limited prospective …
localized hepatocellular carcinoma (HCC) are lacking. Because there are limited prospective …
Clinical risk score to predict pancreatic fistula after pancreatoduodenectomy: independent external validation for open and laparoscopic approaches
…, FG Que, KMR Lombardo, MJ Truty… - Journal of the American …, 2015 - Elsevier
Background A clinical risk score for pancreatic fistula (CRS-PF) was recently reported to
predict postoperative pancreatic fistula (POPF) after pancreatoduodenectomy (PD). An …
predict postoperative pancreatic fistula (POPF) after pancreatoduodenectomy (PD). An …
Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches?
…, FG Que, KM Reid-Lombardo, MJ Truty… - Annals of …, 2014 - journals.lww.com
… The author contribution is as follows: Michael Kendrick, Kris Croome, Michael Farnell,
Florencia Que, KMarie Reid-Lombardo, Mark Truty, and David Nagorney: participated in research …
Florencia Que, KMarie Reid-Lombardo, Mark Truty, and David Nagorney: participated in research …
Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an …
…, DM Nagorney, RL Smoot, MB Farnell, MJ Truty - Journal of the American …, 2016 - Elsevier
Background Patient triage in anatomically resectable, early stage pancreatic ductal
adenocarcinoma (PDAC) with elevated carbohydrate antigen 19-9 (CA 19-9) remains unclear. We …
adenocarcinoma (PDAC) with elevated carbohydrate antigen 19-9 (CA 19-9) remains unclear. We …
Borderline resectable and locally advanced pancreatic cancer: FDG PET/MRI and CT tumor metrics for assessment of pathologic response to neoadjuvant therapy …
BACKGROUND. Imaging biomarkers of response to neoadjuvant therapy (NAT) for pancreatic
ductal adenocarcinoma (PDA) are needed to optimize treatment decisions and long-term …
ductal adenocarcinoma (PDA) are needed to optimize treatment decisions and long-term …
Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases …
J Shindoh, MJ Truty, TA Aloia, SA Curley… - Journal of the American …, 2013 - Elsevier
BACKGROUND: Standardized future liver remnant (sFLR) volume and degree of hypertrophy
after portal vein embolization (PVE) have been recognized as important predictors of …
after portal vein embolization (PVE) have been recognized as important predictors of …